Neuronetics, Inc. (STIM)
NASDAQ: STIM · IEX Real-Time Price · USD
1.925
+0.025 (1.32%)
At close: Jul 19, 2024, 4:00 PM
1.910
-0.015 (-0.78%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

Company Description

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally.

The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.

The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics, Inc.
Neuronetics logo
Country United States
Founded 2003
IPO Date Jun 28, 2018
Industry Diagnostics & Research
Sector Healthcare
Employees 203
CEO Keith J. Sullivan

Contact Details

Address:
3222 Phoenixville Pike
Malvern, Pennsylvania 19355
United States
Phone 877-600-7555
Website neurostar.com

Stock Details

Ticker Symbol STIM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001227636
CUSIP Number 64131A105
ISIN Number US64131A1051
SIC Code 3841

Key Executives

Name Position
Keith J. Sullivan President, Chief Executive Officer and Director
Stephen J. Furlong M.S. Executive Vice President, Chief Financial Officer and Treasurer
W. Andrew Macan Executive Vice President, GC, Chief Compliance Officer and Corporate Secretary
Rusty Page Senior Vice President of Operations and Quality
Lisa Metzner-Rosas Senior Vice President and Chief Marketing Officer
Sara Grubbs Senior Vice President and Chief Revenue Officer
Rick Grubbs Senior Vice President of National Accounts
Cory S. Anderson Senior Vice President of Research & Development and Clinical

Latest SEC Filings

Date Type Title
Jul 18, 2024 144 Filing
Jul 17, 2024 144 Filing
Jul 16, 2024 144 Filing
Jun 28, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jun 6, 2024 8-K Current Report
Jun 3, 2024 8-K Current Report
May 30, 2024 SD Form - SD
May 7, 2024 10-Q Quarterly Report
May 7, 2024 8-K Current Report
May 7, 2024 8-K Current Report